J Bone Metab.  2015 Feb;22(1):29-32. 10.11005/jbm.2015.22.1.29.

Risk of Hip Fractures in Men with Alpha-Blockers: A Nationwide Study Base on Claim Registry

• Seo GH
• Lee YK
• Ha YC

• KMID: 2170062
• DOI: http://doi.org/10.11005/jbm.2015.22.1.29

Abstract

BACKGROUND
Alpha-blocker can result in falling and fractures because of adverse effect such as orthostatic hypotension due to vasodilatory effect. We investigated the association between the alpha-blocker and the risk of osteoporotic hip fractures using a nationwide claim database.
METHODS
We identified 1,051,651 men 65 years of age or older who had prescription records of alpha-blocker from nationwide medical claim database, from 2007 to 2012. Alpha-blockers were classified as non-specific general (NSG), non-specific slow-release (NSSR), uro-specific general (USG), and uro-specific slow release (USSR).
RESULTS
Total of 6,553 hip fractures were observed. The incidences of hip fracture within 1 year were higher than those of the reference periods in all type of alpha-blocker. Hazard ratio peaked at early period of alpha-blocker, and decreased with time, regardless of type of alpha-blocker.
CONCLUSIONS
Use of alpha-blocker is associated with increased risk of hip fracture, especially in early use.

Keyword

Alpha-blocker; Hip fracture; Registries

MeSH Terms

Hip
Hip Fractures*
Humans
Hypotension, Orthostatic
Incidence
Male
Prescriptions
Registries

Figure

• 

  Fig. 1 Hazard ratio of hip fracture after use of alpha-blocker in each type of alpha-blocker. NSG, non-specific general; NSSR, non-specific slow-release; USG, non-specific slow-release; USSR, uro-specific slow release.

Reference

1. Arrighi HM, Metter EJ, Guess HA, et al. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology. 1991; 38:4–8.

2. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185:1793–1803.

3. Chrischilles E, Rubenstein L, Chao J, et al. Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. Clin Ther. 2001; 23:727–743.

4. Butt DA, Mamdani M, Austin PC, et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012; 172:1739–1744.

5. Song HJ, Lee J, Kim YJ, et al. beta1 selectivity of beta-blockers and reduced risk of fractures in elderly hypertension patients. Bone. 2012; 51:1008–1015.

6. Souverein PC, Van Staa TP, Egberts AC, et al. Use of alpha-blockers and the risk of hip/femur fractures. J Intern Med. 2003; 254:548–554.

7. Park C, Ha YC, Jang S, et al. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011; 29:744–751.

8. Yoon HK, Park C, Jang S, et al. Incidence and mortality following hip fracture in Korea. J Korean Med Sci. 2011; 26:1087–1092.

9. Lee YK, Jang S, Jang S, et al. Mortality after vertebral fracture in Korea: analysis of the National Claim Registry. Osteoporos Int. 2012; 23:1859–1865.

10. Park C, Jang S, Jang S, et al. Identification and validation of osteoporotic hip fracture using the national health insurance database. J Korean Hip Soc. 2010; 22:305–311.

11. Lee YK, Ha YC, Park C, et al. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int. 2013; 24:707–711.

12. Kim SH, Ko YB, Lee YK, et al. National utilization of calcium supplements in patients with osteoporotic hip fracture in Korea. J Bone Metab. 2013; 20:99–103.

13. Lee YK, Ha YC, Choi HJ, et al. Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int. 2013; 24:2887–2892.

14. Park C, Ha YC, Jang S, et al. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011; 29:744–751.

15. Feldstein C, Weder AB. Orthostatic hypotension: a common, serious and underrecognized problem in hospitalized patients. J Am Soc Hypertens. 2012; 6:27–39.